LM11A-31 is primarily researched for its potential therapeutic applications in neurodegenerative diseases. It functions as a small molecule ligand for the p75 neurotrophin receptor, which plays a role in neuronal survival and death. This compound has shown promise in preclinical studies for treating conditions such as Alzheimer's disease, amyotrophic lateral sclerosis (ALS), and spinal cord injuries. By modulating the p75 receptor, LM11A-31 helps promote neuronal survival, reduce inflammation, and inhibit apoptosis, offering a potential avenue for neuroprotection. Its ability to cross the blood-brain barrier further enhances its suitability for targeting central nervous system disorders. Ongoing research focuses on optimizing its efficacy and safety for clinical use.